Atrial Fibrillation Management

Initial Treatment

For patients with atrial fibrillation and rapid ventricular response who are hemodynamically stable without heart failure, hypotension, or bronchospasm, the American College of Cardiology recommends intravenous beta-blockers as the first-line treatment 1, 2
Immediate direct-current cardioversion is recommended for patients who are hemodynamically compromised 1, 2

For patients without heart failure, hypotension, or bronchospasm, IV beta-blockers (e.g., metoprolol) are recommended 2
For patients with heart failure with preserved ejection fraction, a beta-blocker or nondihydropyridine calcium channel antagonist is recommended 1, 3
For patients with heart failure with reduced ejection fraction, IV digoxin or amiodarone is recommended to control heart rate acutely 1, 3
For patients with COPD/bronchospasm, a nondihydropyridine calcium channel antagonist (diltiazem or verapamil) is recommended 1, 3
For patients with thyrotoxicosis, beta-blockers are recommended unless contraindicated, and if contraindicated, a nondihydropyridine calcium channel antagonist is recommended 1, 2

The American College of Cardiology advises against using beta-blockers, calcium channel blockers, digoxin, and adenosine as they can accelerate ventricular rate in certain situations 1, 2, 4

IV procainamide or ibutilide may be used to restore sinus rhythm 1, 2
Sotalol is effective for maintaining sinus rhythm after cardioversion at doses ranging from 80 to 160 mg twice daily, and combines Class III antiarrhythmic effects with beta-blocking properties, making it effective for both rhythm and rate control 5
Amiodarone is reserved as a last resort due to potential extracardiac adverse effects, as recommended by the European Heart Journal 6, 7

If monotherapy is insufficient, a combination of digoxin and beta-blocker (or nondihydropyridine calcium channel antagonist in HFpEF) is reasonable 1, 3

Using nondihydropyridine calcium channel blockers in decompensated heart failure can worsen heart failure and cause hemodynamic collapse 1, 3
Using AV nodal blocking agents in WPW syndrome with pre-excited AF can facilitate antegrade conduction through accessory pathway leading to ventricular fibrillation 1, 2, 4
Sotalol can prolong the QT interval and potentially cause torsades de pointes, requiring QT interval monitoring, and is contraindicated in patients with asthma, heart failure, renal insufficiency, or baseline QT prolongation 5
Caution is advised when using sotalol with other QT-prolonging medications 5

The American College of Cardiology recommends anticoagulating for at least 3-4 weeks before and after cardioversion if the AF duration is >48 hours or unknown duration, and targeting an INR of 2-3 if using warfarin for anticoagulation 8
The European Society of Cardiology guidelines recommend anticoagulation based on CHA₂DS₂-VASc score, with the following recommendations:
Score Recommendation
0 No anticoagulation needed
1 Consider anticoagulation
≥2 Anticoagulation recommended [9]
Direct Oral Anticoagulants (DOACs) are preferred over vitamin K antagonists for anticoagulation therapy in patients with atrial fibrillation, as recommended by the American College of Cardiology 4, 10

Score	Recommendation
0	No anticoagulation needed
1	Consider anticoagulation
≥2	Anticoagulation recommended	[9]

The American College of Cardiology emphasizes the importance of ensuring rate control is effective both at rest and during activity 8
Initial heart rate target should be <110 bpm (lenient rate control), as recommended by the European Society of Cardiology 7
Beta-blockers have shown moderate but consistent efficacy to prevent AF recurrence, with a success rate of approximately 70% for rate control in AF, as reported by the American Heart Association 11
Non-dihydropyridine calcium channel blockers (e.g. diltiazem, verapamil) are alternative first-line agents for rate control, with a success rate of approximately 54% of patients, as reported by the American Heart Association 11

The American College of Cardiology recommends medication dosing as follows:

Medication	IV Administration	Oral Maintenance Dose
Metoprolol	2.5-5.0 mg IV bolus (up to 3 doses)	25-100 mg BID
Diltiazem	15-25 mg IV bolus	60-120 mg TID (120-360 mg daily modified release)
Verapamil	2.5-10 mg IV bolus	40-120 mg TID (120-480 mg daily modified release)
Digoxin	0.5 mg IV bolus	0.0625-0.25 mg daily	[7, 9]

Younger patients without structural heart disease may be considered for rhythm control, as recommended by the American College of Physicians 12
Patients with paroxysmal atrial fibrillation may also be considered for rhythm control, according to the American College of Physicians 12
Consider rhythm control when rate control provides inadequate symptom relief, as recommended by the European Society of Cardiology 13
Flecainide and propafenone are suitable for patients without structural heart disease, as stated by the European Society of Cardiology 7
Catheter ablation is indicated for patients with symptomatic atrial ectopics refractory to medical therapy, with success rates of 80-95% reported, as recommended by the American Heart Association 14, 15

Lifestyle modifications, including blood pressure control (target <140/90 mmHg), weight management (target BMI 20-25 kg/m²), regular physical activity (150-300 min/week moderate intensity), and alcohol reduction (≤3 standard drinks per week) are recommended, as recommended by the American Heart Association and European Society of Cardiology guidelines 3, 9

Patients should be monitored for heart rate response, blood pressure, symptoms of heart failure, renal function, and electrolytes within one week of initiating therapy, with a strength of evidence level of recommendation, according to the American College of Cardiology 14
Patients should be followed up within 10 days after initial management and then at least annually, with monitoring for heart rate control, rhythm status, anticoagulation efficacy and safety, and signs of bleeding, as recommended by the American Heart Association 5